Drug self-delivery systems for cancer therapy

Qin, Si‐Yong; Zhang, Aiqing; Cheng, Si‐Xue; Rong, Lei; Zhang, Xian‐Zheng

doi:10.1016/j.biomaterials.2016.10.016

Cited by 475 publications

(294 citation statements)

References 123 publications

Supporting

Mentioning

289

Contrasting

Unclassified

Order By: Relevance

“…[18][19][20][21] To administer a required drug dose in a target location, copious levels of carrier materials have to be used. For intravenous administration, the extensive use of these carrier materials may cause systemic toxicity, such as lipotoxicity, and impose an extra burden for patients to degrade, metabolize, and excrete these carriers.…”

Section: Drug Loading Content (Weight [Wt]%)mentioning

confidence: 99%

High drug-loading nanomedicines: progress, current status, and prospects

Shen

Liu

et al. 2017

IJN

436

268

View full text Add to dashboard Cite

Drug molecules transformed into nanoparticles or endowed with nanostructures with or without the aid of carrier materials are referred to as “nanomedicines” and can overcome some inherent drawbacks of free drugs, such as poor water solubility, high drug dosage, and short drug half-life in vivo. However, most of the existing nanomedicines possess the drawback of low drug-loading (generally less than 10%) associated with more carrier materials. For intravenous administration, the extensive use of carrier materials might cause systemic toxicity and impose an extra burden of degradation, metabolism, and excretion of the materials for patients. Therefore, on the premise of guaranteeing therapeutic effect and function, reducing or avoiding the use of carrier materials is a promising alternative approach to solve these problems. Recently, high drug-loading nanomedicines, which have a drug-loading content higher than 10%, are attracting increasing interest. According to the fabrication strategies of nanomedicines, high drug-loading nanomedicines are divided into four main classes: nanomedicines with inert porous material as carrier, nanomedicines with drug as part of carrier, carrier-free nanomedicines, and nanomedicines following niche and complex strategies. To date, most of the existing high drug-loading nanomedicines belong to the first class, and few research studies have focused on other classes. In this review, we investigate the research status of high drug-loading nanomedicines and discuss the features of their fabrication strategies and optimum proposal in detail. We also point out deficiencies and developing direction of high drug-loading nanomedicines. We envision that high drug-loading nanomedicines will occupy an important position in the field of drug-delivery systems, and hope that novel perspectives will be proposed for the development of high drug-loading nanomedicines.

show abstract

Section: Drug Loading Content (Weight [Wt]%)mentioning

confidence: 99%

High drug-loading nanomedicines: progress, current status, and prospects

Shen

Liu

et al. 2017

IJN

436

268

View full text Add to dashboard Cite

show abstract

“…Among these, chemotherapy has become an important method for most cancer treatments because of its high efficiency compared with other treatments. Unfortunately, traditional chemical drugs have many shortcomings, such as low solubility, poor bioavailability, non-selective distribution and rapid blood clearance 1, 2 . In order to overcome these problems, nanotechnology, such as self-assembled nano-carriers 3–5 , inorganic nano-frames 6 , micelles 7, 8 and liposomes 9, 10 have been employed for drug delivery.…”

Section: Introductionmentioning

confidence: 99%

A novel pH-sensitive carrier for the delivery of antitumor drugs: histidine-modified auricularia auricular polysaccharide nano-micelles

Wang

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The study was aimed to design a novel pH-sensitive carrier to deliver antitumor drugs to increase treatment efficiency. Histidine (His)was used to modify auricularia auricular polysaccharide (AAP) by esterification. Proton nuclear magnetic resonance spectrometry was developed to characterize the His-AAP carrier and the His-AAP Paclitaxel (PTX) micelles were prepared by self-assembled organic solvent evaporation. The formation of His-AAP PTX micelles was confirmed by dynamic light-scattering, transmission electron microscopy and high performance liquid chromatography. It was found that the His-AAP PTX micelles possessed a spherical morphology with an average diameter of 157.2 nm and an 80.3% PTX encapsulation efficiency. In vitro release at pH 7.4, 6.5, 5.0 reached 70%, 71%, and 88%, respectively. The cell viability assay and confocal laser scanning microscope were used to evaluate the cytotoxicity and cell uptake of the His-AAP PTX micelles. Compared with Taxol, the IC50 of the His-AAP PTX micelles were lower after incubating for 24 h, 48 h, or 72 h (0.216 versus 0.199, 0.065 versus 0.060, and 0.023 versus 0.005, respectively). In a test of tumor-bearing mice, the His-AAP PTX micelles significantly inhibited tumor growth. These results showed that His-AAP PTX micelles are a highly promising therapeutic system for anticancer therapy.

show abstract

“…Chemotherapy is an indispensable choice to fight against tumors. However, conventional chemotherapy is far from satisfactory, and the undesirable outcomes of clinical/preclinical chemotherapy may be attributed to the following factors: 1) tumor heterogeneity both among different tumors and within individual tumor; 2) poor bioavailability and side effects resulted from nonspecific drug distribution; 3) drug abuse because of the unsuccessful evaluation on real‐time therapeutic effect; 4) occurrence of chemoresistance at cellular and tumor levels; 5) undesirable immune reactions between exogenous carriers and specific cell surface receptors . To advance the therapeutic effects, researchers have focused on creating smart medicines that are suitable for individual patients.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Qin

Zhang

2018

Small

Self Cite

109

View full text Add to dashboard Cite

Efficacy and safety of chemotherapeutic drugs constitute two major criteria in tumor chemotherapy. Nanomedicines with tumor-targeted properties hold great promise for improving the efficacy and safety. To design targeted nanomedicines, the pathological characteristics of tumors are extensively and deeply excavated. Here, the rationale, principles, and advantages of exploiting these pathological characteristics to develop targeted nanoplatforms for tumor chemotherapy are discussed. Homotypic targeting with the ability of self-recognition to source tumors is reviewed individually. In the meanwhile, the limitations and perspective of these targeted nanomedicines are also discussed.

show abstract

Drug self-delivery systems for cancer therapy

Cited by 475 publications

References 123 publications

High drug-loading nanomedicines: progress, current status, and prospects

High drug-loading nanomedicines: progress, current status, and prospects

A novel pH-sensitive carrier for the delivery of antitumor drugs: histidine-modified auricularia auricular polysaccharide nano-micelles

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

Contact Info

Product

Resources

About